Predictors of clozapine discontinuation in patients with schizophrenia

International Clinical Psychopharmacology

Volumn 26, Issue 6, 2011, Pages 311-315

  Krivoy, Amir ^a,b   Malka, Liron ^a,b   Fischel, Tsvi ^a,b   Weizman, Abraham ^a,b   Valevski, Avi ^a,b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

clozapine; discontinuation; schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; SEIZURE; SOMNOLENCE; SUBSTANCE ABUSE; SUICIDE ATTEMPT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; SUICIDE, ATTEMPTED; TIME FACTORS; UNIVERSITIES; YOUNG ADULT;

EID: 80053611411     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834ab34c     Document Type: Article

References (24)

1. Atkinson JM, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor DM (2007). Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 68:1027-1030. (Pubitemid 47340322)
2. Buchanan RW (1995). Clozapine: efficacy and safety. Schizophr Bull 21:579-591.
3. Buckley P, Thompson P, Way L, Meltzer HY (1994a). Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 151:385-389. (Pubitemid 24081458)
4. Buckley P, Thompson PA, Way L, Meltzer HY (1994b). Substance abuse and clozapine treatment. J Clin Psychiatry 55 (Suppl B):114-116. (Pubitemid 24353032)
5. Ciapparelli A, Dell'Osso L, Bandettini di PA, Carmassi C, Cecconi D, Fenzi M, et al. (2003). Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 64:451-458. (Pubitemid 36547291)
6. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564. (Pubitemid 36682312)
7. Kane JM, Honigfeld G, Singer J, Meltzer H (1988). Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24:62-67.
8. Lay B, Blanz B, Hartmann M, Schmidt MH (2000). The psychosocial outcome of adolescent-onset schizophrenia: a 12-year followup. Schizophr Bull 26:801-816.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223. (Pubitemid 41345943)
10. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610. (Pubitemid 44464569)
11. Meltzer HY (1992). Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18:515-542.
12. Meltzer HY (1997). Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 14:1-20.
13. Meltzer HY (1999). Suicide and schizophrenia: clozapine and the InterSePT study. International Clozaril/Leponex Suicide Prevention Trial. J Clin Psychiatry 60 (Suppl 12):47-50. (Pubitemid 29283184)
14. Moeller FG, Chen YW, Steinberg JL, Petty F, Ripper GW, Shah N, et al. (1995). Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry 7:167-173. (Pubitemid 26105849)
15. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M (2008). Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 69:759-768. (Pubitemid 351838685)
16. Pristach CA, Smith CM (1990). Medication compliance and substance abuse among schizophrenic patients. Hosp Community Psychiatry 41:1345-1348.
17. Remschmidt H, Martin M, Fleischhaker C, Theisen FM, Hennighausen K, Gutenbrunner C, et al. (2007). Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm 114:505-512. (Pubitemid 46474859)
18. Schulte PF (2006). Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 40:683-688.
19. Schulte PF, Cohen D, Bogers JP, van DD, Bakker B (2010). A Dutch guideline for the use of clozapine. Aust NZ J Psychiatry 44:1055-1056.
20. Volavka J (1999). The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry 60 (Suppl 12):43-46. (Pubitemid 29283183)
21. Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer JP, Citrome L, et al. (2004). Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 24:225-228. (Pubitemid 38380848)
22. Weiss KA, Smith TE, Hull JW, Piper AC, Huppert JD (2002). Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 28:341-349. (Pubitemid 35462249)
23. Whiskey E, Wykes T, Duncan-McConnell D, Haworth E, Walsh N, Hastilow S (2003). Continuation of clozapine treatment: practice makes perfect. Psychiatric Bull 27:211-213. (Pubitemid 36681906)
24. Young CR, Longhurst JG, Bowers MB Jr, Mazure CM (1997). The expanding indications for clozapine. Exp Clin Psychopharmacol 5:216-234. (Pubitemid 27346446)